Robinhood's fastest-growing prediction market products are Bitcoin, gold, and crude oil contracts, according to JB Mackenzie, the company's VP and GM of futures and prediction markets. While sports remain the largest category, event contracts related to major economic events like the Federal Reserve's interest-rate decisions are gaining traction. Robinhood offers event contracts that settle quickly, some in as little as 15 minutes, which increases risk but attracts active traders. The company sees prediction markets as a potential fastest-growing business segment alongside its other revenue streams.
Robinhood's fastest-growing contracts in Bitcoin, gold, and crude oil provide context for market activity in digital assets. For readers following major cryptocurrencies, here is Pluang's market snapshot as of Oct 24, 2026 21:01 WIB: out of 50 priced major cryptocurrencies, 5 rose and 43 fell today. Notable movers include SXP (Solar) down 46.27% at Rp37 with a typical hold time of 94 days, BAL (Balancer) up 11.14% at Rp16.297 with a typical hold time of 85 days, and EOS (EOS.IO) up 8.13% at Rp12.649 with a typical hold time of 87 days.
The Royal Canadian Legion has launched its 2026 National Poppy Campaign introducing a new contactless donation method using smartphones, supported by BMO and Toucan Giving technology. This innovation allows volunteers to collect donations via debit, ...
XBiotech Inc. announced the election of Jan-Paul Simard as Co-Chief Executive Officer alongside current CEO Dr. Sushma Shivaswamy, effective October 23, 2026. This leadership change aims to leverage their complementary skills and scientific expertise...
XBiotech Inc. announced the appointment of Sushma Shivaswamy and Jan-Paul Simard as co-chief executive officers, effective October 23, 2026. Shivaswamy, with 17 years at the company, has led scientific operations and was interim CEO since December 20...
Genmab and Incyte announced a Phase 1/2 clinical trial to test a combination of petosemtamab, INCB161734, and standard chemotherapy as a first-line treatment for metastatic colorectal cancer with the KRAS G12D mutation. This mutation is common and li...
Nanobiotix announced positive Phase 1 trial results for JNJ-1900 (NBTXR3), used with radiotherapy and immune checkpoint inhibitors, in 24 heavily pretreated advanced melanoma patients resistant to anti-PD-1 therapies. The treatment showed a 41.7% obj...
